Ken Griffin Arbutus Biopharma Corp Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 23,700 shares of ABUS stock, worth $86,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,700

Previous 93,100 74.54%

Holding current value

$86,268

Previous $240,000 69.58%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.52 - $3.63 $4.66 Million - $6.72 Million	-1,850,929 Reduced 92.74%	144,875 $447,000
Q1 2024 May 15, 2024	BUY	$2.26 - $2.92 $139,771 - $180,590	61,846 Added 3.2%	1,995,804 $5.15 Million
Q4 2023 Feb 14, 2024	SELL	$1.69 - $2.54 $142,330 - $213,916	-84,219 Reduced 4.17%	1,933,958 $4.83 Million
Q3 2023 Nov 14, 2023	SELL	$1.9 - $2.27 $530,090 - $633,318	-278,995 Reduced 12.15%	2,018,177 $4.1 Million
Q2 2023 Aug 14, 2023	BUY	$2.24 - $3.06 $4.65 Million - $6.35 Million	2,076,034 Added 938.8%	2,297,172 $5.28 Million
Q1 2023 May 15, 2023	SELL	$2.23 - $3.1 $324,960 - $451,738	-145,722 Reduced 39.72%	221,138 $670,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $342,082 - $510,437	179,101 Added 95.39%	366,860 $854,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $198,163 - $303,569	105,406 Added 127.99%	187,759 $358,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $554,451 - $887,682	-280,026 Reduced 77.27%	82,353 $223,000
Q1 2022 May 16, 2022	BUY	$2.42 - $3.98 $57,187 - $94,051	23,631 Added 6.98%	362,379 $1.08 Million
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $6,611 - $9,800	-2,126 Reduced 0.62%	338,748 $1.32 Million
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $609,348 - $1.06 Million	229,943 Added 207.28%	340,874 $1.46 Million
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $1.46 Million - $2.05 Million	-585,412 Reduced 84.07%	110,931 $336,000
Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $1.88 Million - $2.89 Million	597,446 Added 604.11%	696,343 $2.32 Million
Q4 2020 Feb 16, 2021	BUY	$2.76 - $4.97 $79,297 - $142,793	28,731 Added 40.95%	98,897 $351,000
Q3 2020 Nov 16, 2020	SELL	$1.75 - $6.2 $2.24 Million - $7.94 Million	-1,280,189 Reduced 94.8%	70,166 $219,000
Q2 2020 Aug 14, 2020	SELL	$0.91 - $2.36 $1.03 Million - $2.66 Million	-1,127,764 Reduced 45.51%	1,350,355 $2.46 Million
Q1 2020 May 15, 2020	BUY	$1.01 - $3.42 $2.45 Million - $8.29 Million	2,423,126 Added 4406.24%	2,478,119 $2.5 Million
Q4 2019 Feb 14, 2020	BUY	$0.87 - $2.89 $37,439 - $124,368	43,034 Added 359.85%	54,993 $153,000
Q2 2019 Aug 14, 2019	SELL	$1.46 - $4.44 $3,308 - $10,061	-2,266 Reduced 15.93%	11,959 $25,000
Q1 2019 May 15, 2019	SELL	$3.41 - $4.57 $219,576 - $294,271	-64,392 Reduced 81.91%	14,225 $0
Q2 2018 Aug 10, 2018	BUY	$5.0 - $7.35 $69,100 - $101,577	13,820 Added 21.33%	78,617 $0
Q1 2018 May 11, 2018	BUY	$4.4 - $6.05 $158,316 - $217,685	35,981 Added 124.86%	64,797 $324,000
Q4 2017 Feb 09, 2018	BUY	$4.45 - $7.7 $128,231 - $221,883	28,816	28,816 $146,000

Others Institutions Holding ABUS

# of Institutions

150

Shares Held

97.5M

Call Options Held

3.49M

Put Options Held

421K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $546M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account